IA Mayer
Vanderbilt University · 44 works · 462 citations · h-index 10
Top works
- Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
- Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
- Breast Cancer
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
- Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
- NCCN Guidelines Insights: Breast Cancer, Version 1.2017
- Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- The PI3K/AKT Pathway as a Target for Cancer Treatment
- Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
- Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results
- Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006
- Resistance to Trastuzumab in Breast Cancer
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology